Skip to main content
SpringerLink
Log in

The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats

  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

Summary.

Levodopa treatment has been shown to increase plasma homocysteine levels in Parkinson’s disease (PD) patients and this may lead to an increased risk for coronary arterial diseases. Levodopa is metabolised via O-methylation by catechol-O-methyltransferase (COMT) using S-adenosyl-L-methionine (SAM) as the methyl donor, this leading to the subsequent formation of homocysteine. In this study, the effects of the COMT inhibitor, entacapone, on levodopa-induced hyperhomocysteinaemia were studied in rats. Using a single dose acute treatment paradigm, entacapone (10 or 30 mg/kg) prevented the levodopa (30 or 100 mg/kg) induced rise in plasma homocysteine levels in a dose-dependent manner. Five-day sub-chronic treatment with levodopa (3 × 100 mg/kg per day) resulted in a marked rise in plasma homocysteine levels when measured 2 hours post-treatment on Day 5. These levels fell but remained greater than baseline at 8 hours post-treatment on Day 5. Consistent with findings in the acute treatment test paradigm, the co-administration of entacapone (30 mg/kg) significantly (p<0.001) reduced levodopa-induced hyperhomocysteinaemia for up to 2 hours post-treatment on Day 5 of the sub-chronic study. These results suggest that entacapone may reduce levodopa-induced hyperhomocysteinaemia in PD patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • P Allain A Le Bouil E Cordillet L Le Quay H Bagheri JL Montastruc (1995) ArticleTitleSulfate and cysteine levels in the plasma of patients with Parkinson’s disease. Neurol Toxicol 16 527–530

    Google Scholar 

  • T Apeland MA Mansoor RE Strandjord O Kristensen (2000) ArticleTitleHomocysteine concentrations and methionine loading in patients on antiepileptic drugs. Acta Neurol Scand 101 217–223 Occurrence Handle10.1034/j.1600-0404.2000.101004217x./ Occurrence Handle10770516

    Article  PubMed  Google Scholar 

  • F Blandini R Fancellu E Martignoni A Mangiagalli C Pacchetti A Samuele G Nappi (2001) ArticleTitlePlasma homocysteine and L-DOPA metabolism in patients with Parkinson disease. Clin Chem 47 1102–1104 Occurrence Handle11375298

    PubMed  Google Scholar 

  • B Boudikova C Szumlanski B Maidak R Weinshilboum (1990) ArticleTitleHuman liver catechol-O-methyltransferase pharmacogenetics. Clin Pharmacol Ther 48 381–389 Occurrence Handle10.1016/0163-7258(90)90056-8 Occurrence Handle2225698

    Article  PubMed  Google Scholar 

  • CJ Boushey SA Beresford GS Omenn AG Motulsky (1995) ArticleTitleA quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274 1049–1057 Occurrence Handle10.1001/jama.274.13.1049 Occurrence Handle7563456

    Article  PubMed  Google Scholar 

  • L Brattstrom DE Wilcken J Ohrvik L Brudin (1998) ArticleTitleCommon methylenetetrahydro-folate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 98 2520–2526 Occurrence Handle9843457

    PubMed  Google Scholar 

  • R Clarke L Daly K Robinson E Naughten S Cahalane B Fowler I Graham (1991) ArticleTitleHyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 324 1149–1155 Occurrence Handle2011158

    PubMed  Google Scholar 

  • K Fassbender O Mielke T Bertsch B Nafe S Fröschen M Hennerici (1999) ArticleTitleHomocysteine in cerebral macroangiography and microangiopathy. Lancet 353 1586–1587 Occurrence Handle10.1016/S0140-6736(99)00309-8 Occurrence Handle10334261

    Article  PubMed  Google Scholar 

  • M Forsberg M Lehtonen M Heikkinen J Savolainen T Järvinen PT Männistö (2003) ArticleTitlePharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat. J Pharmacol Exp Ther 304 498–506 Occurrence Handle10.1124/jpet.102.042846 Occurrence Handle12538800

    Article  PubMed  Google Scholar 

  • GJ Hankey JW Eikelboom (1999) ArticleTitleHomocysteine and vascular disease. Lancet 354 407–413 Occurrence Handle10.1016/S0140-6736(98)11058-9 Occurrence Handle10437885

    Article  PubMed  Google Scholar 

  • W Kuhn R Roebroek H Blom D van Oppenraaij H Przuntek A Kretschmer T Buttner D Woitalla T Muller (1998) ArticleTitleElevated plasma levels of homocysteine in Parkinson’s disease. Eur Neurol 40 IssueID4 225–227 Occurrence Handle10.1159/000007984 Occurrence Handle9813406

    Article  PubMed  Google Scholar 

  • MS Lee CH Lyoo I Ulmanen A-C Syvänen JO Rinne (2001) ArticleTitleGenotypes of catechol-O-methyltransferase and response to levodopa in patients with Parkinson’s disease. Neurosci Lett 298 131–134 Occurrence Handle10.1016/S0304-3940(00)01749-3 Occurrence Handle11163295

    Article  PubMed  Google Scholar 

  • MS Lee HS Kim EK Cho JH Lim JO Rinne (2002) ArticleTitleCOMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson’s disease. Neurology 58 564–567 Occurrence Handle11865133

    PubMed  Google Scholar 

  • T Lotta J Vidgren C Tilgmann I Ulmanen K Melén I Julkunen J Taskinen (1995) ArticleTitleKinetics of human soluble and membrane-bound catechol-O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 34 4202–4210 Occurrence Handle10.1021/bi00013a008 Occurrence Handle7703232

    Article  PubMed  Google Scholar 

  • J Ma MJ Stampfer CH Hennekens P Frosst J Selhub J Horsford MR Malinow WC Willett R Rozen (1996) ArticleTitleMethylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation 94 2410–2416 Occurrence Handle8921781

    PubMed  Google Scholar 

  • JW Miller B Shukitt-Hale R Villalobos-Molina MR Nadeau J Selhub JA Joseph (1997) ArticleTitleEffect of L-Dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats. Clin Neuropharmacol 20 55–66 Occurrence Handle9037574

    PubMed  Google Scholar 

  • JW Miller J Selhub MR Nadeau CA Thomas RG Feldman PA Wolf (2003) ArticleTitleEffect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology 60 1125–1129 Occurrence Handle12682318

    PubMed  Google Scholar 

  • T Müller B Werne B Fowler W Kuhn (1999) ArticleTitleNigral endothelial dysfunction, homocysteine, and Parkinson’s disease [Letter]. Lancet 354 126–127 Occurrence Handle10.1016/S0140-6736(99)01660-8 Occurrence Handle10408491

    Article  PubMed  Google Scholar 

  • T Müller D Woitala Hauptmann B Fowler W Kuhn (2001) ArticleTitleDecrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson’s disease. Neurosci Lett 308 54–56 Occurrence Handle10.1016/S0304-3940(01)01972-3 Occurrence Handle11445284

    Article  PubMed  Google Scholar 

  • T Müller D Woitala B Fowler W Kuhn (2002) ArticleTitle3-OMD and homocysteine plasma levels in parkinsonian patients. J Neural Transm 109 175–179 Occurrence Handle10.1007/s007020200013 Occurrence Handle12075857

    Article  PubMed  Google Scholar 

  • PT Männistö S Kaakkola (1989) ArticleTitleNew Selective COMT inhibitors: useful adjuncts for Parkinson’s disease? Trends Pharmacol Sci 10 54–56 Occurrence Handle10.1016/0165-6147(89)90075-8 Occurrence Handle2655238

    Article  PubMed  Google Scholar 

  • E Nissinen I-B Lindén E Schultz P Pohto (1992) ArticleTitleBiochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn Schmiedebergs Arch Pharmacol 346 262–266 Occurrence Handle10.1007/BF00173538 Occurrence Handle1407012

    Article  PubMed  Google Scholar 

  • Parkinson Study Group (1997) Entacapone improves motor fluctuations in levodopa-treated Parkinson’s disease patients. Ann Neurol 42: 747–755

  • S Reutens P Sachdev (2002) ArticleTitleHomocysteine in neuropsychiatric disorders of the elderly. Int J Geriatr Psychiatry 17 859–864 Occurrence Handle10.1002/gps.723 Occurrence Handle12221661

    Article  PubMed  Google Scholar 

  • Rinne UK, Larsen JP, Siden Å, Worm-Petersen J, and the Nomecomt Study Group (1998) Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology 51: 1309–1314

    Google Scholar 

  • K Robinson K Arheart H Refsum L Brattström G Boers P Ueland P Rubba R Palma-Reis R Meleady L Daly J Witteman I Graham (1998) ArticleTitleLow circulating folate and vitamin B6 concentrations. Risk factors for stroke, peripheral vascular disease, and coronary artery disease. European COMAC Group. Circulation 97 437–443 Occurrence Handle9490237

    PubMed  Google Scholar 

  • JD Rogers A Sanchez-Saffon AB Frol R Diaz-Arrastia (2003) ArticleTitleElevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Arch Neurol 60 59–64 Occurrence Handle12533089

    PubMed  Google Scholar 

  • PM Ueland S Hustad J Schneede H Refsum SE Vollse (2001) ArticleTitleBiological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 22 195–201 Occurrence Handle10.1016/S0165-6147(00)01675-8 Occurrence Handle11282420

    Article  PubMed  Google Scholar 

  • FM van Bockxmeer CD Mamotte SD Vasikaran RR Taylor (1996) ArticleTitleMethylenetetrahydrofolate reductase gene and coronary heart disease. Circulation 94 3074–3078 Occurrence Handle8989110

    PubMed  Google Scholar 

  • EGJ Vermeulen CDA Stehouwer JWR Twisk M van den Berg SC de Jong AJC Mackaay CMC van Campen FC Visser CAJM Jakobs EJ Bulterijs JA Rauwerda (2000) ArticleTitleEffect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. Lancet 355 517–522 Occurrence Handle10.1016/S0140-6736(99)07391-2 Occurrence Handle10683000

    Article  PubMed  Google Scholar 

  • K Yasui H Kowa K Nakaso T Takeshima K Nakashima (2000) ArticleTitlePlasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology 55 437–440 Occurrence Handle10932284

    PubMed  Google Scholar 

  • K Yasui K Nakaso H Kowa T Takeshima K Nakashima (2003) ArticleTitleLevodopa-induced hyperhomocysteinaemia in Parkinson’s disease. Acta Neurol Scand 108 66–67 Occurrence Handle10.1034/j.1600-0404.2003.00135.x Occurrence Handle12807397

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Orion Pharma, Espoo, Finland

    E. Nissinen & H. Nissinen

  2. Department of Pharmacy, University of Helsinki, Helsinki, Finland

    H. Larjonmaa

  3. Institute of Biomedicine (Pharmacology), University of Helsinki, Helsinki, Finland

    H. Larjonmaa, A. Väänänen, T. Helkamaa, I. Reenilä & P. Rauhala

Authors
  1. E. Nissinen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Nissinen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Larjonmaa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Väänänen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T. Helkamaa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. I. Reenilä
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P. Rauhala
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nissinen, E., Nissinen, H., Larjonmaa, H. et al. The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats. J Neural Transm 112, 1213–1221 (2005). https://doi.org/10.1007/s00702-004-0262-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00702-004-0262-4

Search

Navigation